Management of Type 2 Diabetes (NICE Guideline)

Summary of NICE guidance on treatment of type 2 diabetes.

NICE recommends that care be tailored to the needs and circumstances of the individual patient, taking into account their personal preferences, comorbidities, risks from polypharmacy, and ability to benefit from long-term interventions.

 Download a pdf version of the above chart.

Adapted from: NICE Clinical Guideline 28 (December 2015; updated May 2017) - Type 2 diabetes in adults: management.


KEYWORDS: Canagliflozin | Dapagliflozin | DPP4 inhibitor | Empagliflozin | Exenatide | Glitazones | GLP-1 agonists | Insulin detemir | Insulin glargine | Insulin secretagogues | Linagliptin | Liraglutide | Lixisenatide | Metformin | Monitoring | Pioglitazone | Repaglinide | Saxagliptin | SGLT2 inhibitors | Sitagliptin | Sulfonylureas | Vildagliptin


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in